Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

ConvaTec sees profits jump by over a third in first half

The FTSE 250 medical products company recorded an operating profit for the period of US$122mln, a 31.5% increase on the same period last year
Medical equipment
Revenues in the first half also jumped 10.8% to US$921.3mln

ConvaTec Group PLC (LON:CTEC) reported a profit increase of over 30% in the first half of the year as revenues climbed over 10% year-on-year.

The FTSE 250 medical products company recorded an operating profit (EBIT) for the period of US$122mln, a 31.5% increase on the same period last year, while revenues climbed 10.8% to US$921.3mln.

READ: ConvaTec 2017 profits fall on supply issues and lower sales of new products

The group also saw revenue growth across all of its divisions, with Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Devices rising 6.6%, 4.4%, 25.7%, and 12.2% respectively in the period.

The interim dividend was also raised to 1.717 cents from 1.4 cents in the same period a year ago.

ConvaTec also provided an update on its backorder catalogue, which ti said had returned to normal levels.

The results will be a positive sign for investors as the firm seeks to perform better than 2017 when it suffered a 3.3% decline in profits as supply issues and low sales of new products dragged on earnings.

In its outlook, the company left it expectations unchanged, forecasting organic revenue growth of between 2.5%-3% for the full year and an adjusted EBIT margin of between 24%-25%.

Paul Moraviec, group chief executive of ConvaTec, said that the company had delivered “a solid performance and made good progress in many areas” in the first half.

He added that despite strong demand for new products in the firm’s advanced wounds divisions being offset by headwinds against some older products “recent positive trends and early results from…growth initiatives” meant the group was confident of an improved performance in the division in the second half.

In a note to clients, analysts at City broker Numis upped their target price for the group to 220p from 180p, noting that the appointment of Stephen Bonnelycke from US health products company Hollister Inc as president of the ostomy division, in addition to the previous appointment of Sten Scheibye as non-executive director, were strong hires who could revive the division which had underperformed in recent years.

In mid-morning trading, ConvaTec shares were up 3.9% at 229p.

View full CTEC profile View Profile

ConvaTec Group PLC Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
myLotus testing kit
October 31 2018
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use